Cas:57076-00-3 2-methylsulfonylbenzenecarboximidamide manufacturer & supplier

Chemical Name:2-methylsulfonylbenzenecarboximidamide

CAS.NO:57076-00-3

Synonyms:2-Methylsulfonyl-benzamidin

Molecular Formula:C₈H₁₀N₂O₂S

Molecular Weight:198.24200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:92.39000

Exact Mass:198.04600

LogP:2.25500

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Methylsulfonyl-benzamidin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Methylsulfonyl-benzamidin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methylsulfonyl-benzamidin Use and application,2-Methylsulfonyl-benzamidin technical grade,usp/ep/jp grade.

Related News: In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being. 2-methylsulfonylbenzenecarboximidamide manufacturer Australia has started denying entry to all travelers who have come from or transited through mainland China. 2-methylsulfonylbenzenecarboximidamide supplier Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. 2-methylsulfonylbenzenecarboximidamide vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 2-methylsulfonylbenzenecarboximidamide factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.